Preoperative breast MRI for newly diagnosed ductal carcinoma in situ: Imaging features and performance in a multicenter setting (ECOG-ACRIN E4112 trial)

Shinn Huey S. Chou, Justin Romanoff, Constance D. Lehman, Seema A. Khan, Ruth Carlos, Sunil S. Badve, Jennifer Xiao, Ralph L. Corsetti, Sara H. Javid, Derrick W. Spell, Linda K. Han, Jennifer L. Sabol, John R. Bumberry, Ilana F. Gareen, Bradley S. Snyder, Constantine Gatsonis, Lynne I. Wagner, Antonio C. Wolff, Kathy D. Miller, Joseph A. SparanoChristopher E. Comstock, Habib Rahbar

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: There are limited data from clinical trials describing preoperative MRI features and performance in the evaluation of mammographically detected ductal carcinoma in situ (DCIS). Purpose: To report qualitative MRI features of DCIS, MRI performance in the identification of additional disease, and associations of imaging features with pathologic, genomic, and surgical outcomes from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E4112 trial. Materials and Methods: Secondary analyses of a multicenter prospective clinical trial from the ECOG-ACRIN Cancer Research Group included women with DCIS diagnosed with conventional imaging techniques (mammography and US), confirmed via core-needle biopsy (CNB), and enrolled between March 2015 and April 2016 who were candidates for wide local excision (WLE) based on conventional imaging and clinical examination results. DCIS MRI features and pathologic features from CNB and excision were recorded. Each woman without invasive upgrade of the index DCIS at WLE received a 12-gene DCIS score. MRI performance metrics were calculated. Associations of imaging features with invasive upgrade, dichotomized DCIS score (,39 vs ≥39), and single WLE success were estimated in uni- and multivariable analyses. Results: Among 339 women (median age, 60 years; interquartile range, 51-66 years), most DCIS cases showed nonmass enhancement (NME) (195 of 339 [58%]) on MRI scans with larger median size than on mammograms (19 mm vs 12 mm; P <.001). Positive predictive value of MRI-prompted CNBs was 32% (21 of 66) (95% CI: 22, 44), yielding an additional cancer detection rate of 6.2% (21 of 339) (95% CI: 4.1, 9.3). MRI false-positive rate was 14.2% (45 of 318) (95% CI: 10.7, 18.4). No imaging features were associated with invasive upgrade or DCIS score (P =.05 to P =.95). Smaller size and focal NME distribution at MRI were linked to single WLE success (P <.001). Conclusion: Preoperative MRI depicted ductal carcinoma in situ (DCIS) diagnosed with conventional imaging most commonly as nonmass enhancement, with larger median span than mammography, and additional cancer detection rate of 6.2%. MRI features of this subset of DCIS did not enable prediction of pathologic or genomic outcomes.

Original languageEnglish (US)
Pages (from-to)66-77
Number of pages12
JournalRADIOLOGY
Volume301
Issue number1
DOIs
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Preoperative breast MRI for newly diagnosed ductal carcinoma in situ: Imaging features and performance in a multicenter setting (ECOG-ACRIN E4112 trial)'. Together they form a unique fingerprint.

Cite this